Emerging drugs for myelofibrosis

le Atallah, Ehab, Verstovsek, Srdan
Foilsithe in Expert Opin Emerg Drugs (2012)

Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms

le Atallah, Ehab, Verstovsek, Srdan
Foilsithe in Expert Rev Anticancer Ther (2009)

Quality of life and long term therapy in patients with chronic myeloid leukemia

le Flynn, Kathryn E., Atallah, Ehab
Foilsithe in Curr Hematol Malig Rep (2016)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?

le Atallah, Ehab, Schiffer, Charles A
Foilsithe in Haematologica (2020)

Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): The Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT)

le Atallah, Ehab, Bylow, Kathryn, Troy, Jesse, Saber, Wael
Foilsithe 2014

Dasatinib dose management for the treatment of chronic myeloid leukemia

le Talpaz, Moshe, Saglio, Giuseppe, Atallah, Ehab, Rousselot, Philippe
Foilsithe in Cancer (2018)

Chronic Myeloid Leukemia- The Promise of Tyrosine Kinase Inhibitor Discontinuation

le Narra, Ravi Kishore, Flynn, Kathryn E., Atallah, Ehab
Foilsithe in Curr Hematol Malig Rep (2017)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

le Randhawa, Jasleen, Ostojic, Alen, Vrhovac, Radovan, Atallah, Ehab, Verstovsek, Srdan
Foilsithe 2012

Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide

le Atallah, Ehab, Abrams, Judith, Ayash, Lois, Bentley, Gail, Abidi, Muneer, Ratanatharathorn, Voravit, Uberti, Joseph
Foilsithe 2010

Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

le Flynn, Kathryn E., Myers, Judith M., D'Souza, Anita, Schiffer, Charles A., Thompson, James E., Atallah, Ehab
Foilsithe in Oncologist (2019)

Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy

le Schneidewend, Robert, Hosking, Paul, Brazauskas, Ruta, Peterson, Jess, Beaudin, Carlie, Michaelis, Laura, Atallah, Ehab, Hari, Parameswaran, Carlson, Karen
Foilsithe in Acta Haematol (2018)

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I

le Mesa, Ruben A., Verstovsek, Srdan, Gupta, Vikas, Mascarenhas, John, Atallah, Ehab, Burn, Timothy, Sun, William, Sandor, Victor, Gotlib, Jason
Foilsithe in Clin Lymphoma Myeloma Leuk (2014)

Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension

le Yan, Matthew, Geyer, Holly, Mesa, Ruben, Atallah, Ehab, Callum, Jeannie, Bartoszko, Justyna, Yee, Karen, Maganti, Manjula, Wong, Florence, Gupta, Vikas
Foilsithe in Clin Lymphoma Myeloma Leuk (2014)

In Reply

le Flynn, Kathryn E., Vanness, David J., Myers, Judith M., D'Souza, Anita, Schiffer, Charles A., Thompson, James E., Atallah, Ehab
Foilsithe in Oncologist (2019)

Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)

le Saber, Wael, Cutler, Corey S., Nakamura, Ryotaro, Zhang, Mei-Jie, Atallah, Ehab, Rizzo, J. Douglas, Maziarz, Richard T., Cortes, Jorge, Kalaycio, Matt E., Horowitz, Mary M.
Foilsithe 2013

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

le Verstovsek, Srdan, Gotlib, Jason, Gupta, Vikas, Atallah, Ehab, Mascarenhas, John, Quintas-Cardama, Alfonso, Sun, William, Sarlis, Nicholas J, Sandor, Victor, Levy, Richard S, Kantarjian, Hagop M, Mesa, Ruben A
Foilsithe 2013

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia

le Jain, Nitin, Stock, Wendy, Zeidan, Amer, Atallah, Ehab, McCloskey, James, Heffner, Leonard, Tomlinson, Benjamin, Bhatnagar, Bhavana, Feingold, Jay, Ungar, David, Chao, Grace, Zhang, Xiaoyan, Qin, Yajuan, Havenith, Karin, Kantarjian, Hagop, Wieduwilt, Matthew J.
Foilsithe in Blood Adv (2020)

Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study

le Atallah, Ehab, Logan, Brent, Chen, Min, Cutler, Corey, Deeg, Joachim, Jacoby, Meagan, Champlin, Richard, Nishihori, Taiga, Confer, Dennis, Gajewski, James, Farnia, Stephanie, Greenberg, Peter, Warlick, Erica, Weisdorf, Daniel, Saber, Wael, Horowitz, Mary M., Rizzo, J. Douglas
Foilsithe in JAMA Oncol (2019)

A Phase 2 Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

le Kantarjian, Hagop M., Lioure, Bruno, Atallah, Ehab, Leguay, Thibaut, Kelly, Kevin, Marolleau, Jean-Pierre, Escoffre-Barbe, Martine, Thomas, Xavier G, Kim, Stella K., Cortes, Jorge, Jabbour, Elias, O'Brien, Susan, Bories, Pierre, Oprea, Corina, Hatteville, Laurence, Dombret, Hervé
Foilsithe in Clin Lymphoma Myeloma Leuk (2015)

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study

le Garcia-Manero, Guillermo, Abaza, Yasmin, Takahashi, Koichi, Medeiros, Bruno C., Arellano, Martha, Khaled, Samer K., Patnaik, Mrinal, Odenike, Olatoyosi, Sayar, Hamid, Tummala, Mohan, Patel, Prapti, Maness-Harris, Lori, Stuart, Robert, Traer, Elie, Karamlou, Kasra, Yacoub, Abdulraheem, Ghalie, Richard, Giorgino, Ruben, Atallah, Ehab
Foilsithe in Blood Adv (2019)